RINGER'S INJ 860 MG / 100 ML
SODIUM CHLORIDE : 860 MG / 100 ML POTASSIUM CHLORIDE : 30 MG / 100 ML CALCIUM CHLORIDE : 33 MG / 100 ML · DIN 00060925 · BAXTER CORPORATION
Health Canada status: CANCELLED POST MARKET
What is RINGER'S INJ?
RINGER'S INJ 860 MG / 100 ML contains SODIUM CHLORIDE : 860 MG / 100 ML POTASSIUM CHLORIDE : 30 MG / 100 ML CALCIUM CHLORIDE : 33 MG / 100 ML. It is listed in the Health Canada Drug Product Database under DIN 00060925, held by BAXTER CORPORATION, supplied as LIQUID for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 15-Jul-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is RINGER'S INJ used for?
Ringer’s Injection, USP is indicated as a source of water and electrolytes.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00060925 |
|---|---|
| Brand name | RINGER'S INJ |
| Generic / active ingredient | SODIUM CHLORIDE : 860 MG / 100 ML POTASSIUM CHLORIDE : 30 MG / 100 ML CALCIUM CHLORIDE : 33 MG / 100 ML |
| Manufacturer | BAXTER CORPORATION |
| Strength | 860 MG / 100 ML |
| Dosage form | LIQUID |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | B05BB01 ELECTROLYTES |
| AHFS class | 40:12.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 15-Jul-2016 |
| Original market date | 1990-12-31 00:00:00 |
How is it stored and handled?
Store between 15ºC and 25ºC.
How is it supplied?
1000 mL
What can be used instead?
Other Canadian products sharing ATC code B05BB01 ELECTROLYTES. 10 of 20 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| (20MMOL/L) POTASSIUM CHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION USP | 150 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00786209 |
| (40 MMOL/L) POTASSIUM CHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION USP | 300 MG / 100 ML | LIQUID | BAXTER CORPORATION | MARKETED | DIN 00786217 |
| ISOLYTE S (MULTI-ELECTROLYTE INJECTION) | 530 MG / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | DIN 01931628 |
| ISOLYTE S PH 7.4 (MULTI-ELECTROLYTE INJECTION) | 820 MCG / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | DIN 01931679 |
| LACTATED RINGER'S INJECTION | 3.1 MG | SOLUTION | ICU MEDICAL CANADA INC | MARKETED | DIN 00039470 |
| LACTATED RINGER'S INJECTION USP | 20 MG / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | DIN 01931636 |
| LACTATED RINGER'S INJECTION, USP | 310 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00061085 |
| PLASMA-LYTE A INJECTION | 30 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02339358 |
| POTASSIUM CHLORIDE IN LACTATED RINGER'S INJECTION | 20 MG / 100 ML | LIQUID | BAXTER CORPORATION | MARKETED | DIN 02243421 |
| POTASSIUM CHLORIDE IN SODIUM CHLORIDE INJECTION USP | 450 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02269414 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.